Otsuki Toshifumi_No.5
Selected journal : Science
An in-body networking system for communication between wearable and implantable therapeutics
What is the main question of the paper?
Inspired by the ionic signaling of the nervous system, can body tissue itself serve as the conductive medium for signal transmission—in place of power-hungry radio-frequency (RF) electronics—to build a syringe-injectable, near-zero-standby-power in-body network (SWANS) that gives wearables and multiple implants coordinated, full-body communication and control?
How did the anthor address the question?
■Step1
Ex vivo circuit engineering and multiplexing validation: Using only passive components—resistors, capacitors, transistors, and comparators—the authors built syringe-implantable receiver circuits that respond selectively to characteristic voltage-pulse magnitudes and pulse lengths. The resulting voltage gradients were detected across >30 cm of ex vivo tissue and to a depth of 14 cm (Fig. 1, L and M), enabling independent, multiplexed control of separate implants (Fig. 1K).
■Step2
In vivo biocompatibility and 2-month stability (rats): A wearable hub with skin-penetrating microneedles was interfaced with subcutaneous, intraperitoneal, and gastrointestinal implants. Communication was maintained over a full 2-month deployment by raising the applied voltage to compensate for the rise in impedance from fibrotic encapsulation, and histological evaluation (H&E and Masson's trichrome staining, plus apoptosis, proliferation, and oxidative-stress markers) showed no tissue, nerve, muscle, or organ damage (Fig. 3E; figs. S18–S20).
■Step3
In vivo closed-loop, full-body neurostimulation: In moving rats, strain sensors on the forelimbs wirelessly and selectively triggered distinct implantable sciatic-nerve stimulators on the hindlimbs via cross-body ionic signaling, establishing a limb-specific, sensor-driven closed loop spanning the whole body (Fig. 4).
What is the strength of the paper?
The central move is to relocate address-selection logic from active digital transceivers to tissue conduction and passive circuit thresholds: the body's own ionic gradient, combined with a handful of passive components (resistor, capacitor, and transistor-type thresholds), lets each implant “listen” only for its own characteristic voltage and pulse signature, with no microcontroller, antenna, or active standby draw. This lets the same architecture achieve three properties that normally trade off against one another: near-zero standby power, extending device lifetime by >15x relative to BLE and NFC (Fig. 1, F and G); submillimeter, syringe-injectable dimensions (as small as 1 mm in diameter for the minimum communication node, <3 mm in width once a battery is added); and independently addressable, multi-device control (Fig. 1, H–K). The authors then validate the whole pipeline not in a dish but as a full sensor-to-actuator closed loop in an intact, moving animal (Fig. 4). One caveat is worth flagging: because addressing relies on passive voltage thresholds rather than active digital error correction, maintaining signal fidelity already required compensatory increases in the applied voltage in rats as fibrotic encapsulation built up over just 2 months (fig. S18). How this threshold-based scheme holds up against the more variable impedance, motion, and tissue heterogeneity of a much larger human body over years, rather than months, is an open question the authors themselves flag for future work.
Comment
This study presents an innovative in-body communication platform that uses tissue as a conductive medium to link wearable and implantable bioelectronic devices. Its low-power, syringe-injectable design and ability to selectively control multiple implants suggest strong potential for future closed-loop therapeutic systems. Further validation in large animals and long-term safety studies will be important before clinical translation.
Comment by Du Yilin
